Drug Alerts and Special Reports

The BuyandBill.com newsletter provides important information pertaining to key reimbursement related events for new and existing office-administered products. Our newsletter is sent from BuyandBill.com on behalf of pharma manufacturers. The newsletter includes the following information: C-Code alerts, J-code alerts, NCCN alerts, New NDC alerts, Updates on Pricing information, and more. Click here to opt in to our newsletter.

Important YCANTH J-Code CMS Part B Payment Information – 5/14/24

See new phase 3 results for patients with previously treated cervical cancer – 5/10/24

Permanent J-Code for DOCIVYX (docetaxel): J9172 – 4/29/24

Samsung Bioepis Biosimilar Market Report 5th Edition, Q2 2024 – 4/8/24

New Indication for Merck Product – 4/4/24

Permanent J-Codes for late-onset Pompe disease treatment option – 3/29/24

Permanent J Code for EYLEA® HD (aflibercept) Injection 8 MG – 3/26/24

Arbimed Partners with BuyandBill – 3/25/24

Permanent J-Code for APHEXDA® (motixafortide): J2277 – 3/21/24

Permanent J-Code for YCANTH® (cantharidin): J7354 – 3/20/24

Permanent J-Code for a New 4F-PCC Available April 1, 2024 – 3/19/24

Permanent J-Code for IZERVAY Effective 4/1/2024 – 3/18/24